38 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
clinical trial. The amendment will include an increase in the patients’ SOFA score range, effectively allowing recruitment of patients with higher levels … Phase I/II clinical trial of Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancers. Recruitment
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
the recruitment of patients with higher levels of sepsis severity. Additionally, the amended protocol provides for two cohorts (treatment and placebo) rather … with the Company’s planned timeline for the initiation of recruitment as per the amended protocol,” stated Oren Hershkovitz, CEO of Enlivex. “Therefore
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Apr 22
Report of Foreign Private Issuer
8:15am
severe/critical patients were not eligible for recruitment into the trial, either because COVID-19 was not the reason for their severe/critical condition … -prioritize its COVID-19 program, the Company plans to cease recruitment of patients into the Phase II trial. Given the slow recruitment, the total
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Sep 21
Report of Foreign Private Issuer
6:02am
from leading Israeli hospitals, and we are committed to accelerate the patient’s recruitment by opening many sites both in Israel and specific EU … ) and the effect of such changes on pace of patient recruitment into clinical trials, manufacturing delays, and changes in market opportunities. All
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
27 Oct 15
Current report (foreign)
12:00am
and Israel, further recruitment has been terminated, with the aim of beginning a Phase 3 study. These 25 patients remain in the Phase 2 study. To date, 22 … , based on the positive signals seen in the first 25 patients enrolled in Canada and Israel, further recruitment was terminated with the aim
6-K
EX-99.1
2cu2jx6awp8 p9jfmnp
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
6-K
EX-99.1
lq7ahm
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
tpyp2696v
1 Oct 20
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
6:06am
6-K
EX-99.1
1vk ezo68
16 Apr 24
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
dgiu43g cuqkr
19 Aug 19
Report of Foreign Private Issuer
7:31am
6-K
EX-99.1
2rey771al bc
24 Feb 20
Report of Foreign Private Issuer
6:30am
6-K
EX-99.1
yqug8qx6fc5dapx h0
17 Aug 22
Current Report
8:02am
6-K
EX-99.1
1ip2a7kgg15hvxp6o
6 Jun 22
Report of Foreign Private Issuer
8:03am
6-K
EX-99.1
uheukk5sy0q 2uys
21 Nov 14
Bio Blast Pharma Reports Third Quarter Financial Results
12:00am
6-K
EX-99.1
xqicvd 5e3jbv0ar9vel
12 Sep 22
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
fukq1xf
9 May 22
Report of Foreign Private Issuer
9:10am
6-K
EX-99.2
515n086dx7hh7zk0o
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
m6er6vxnwi98vdvd1y
31 May 22
Report of Foreign Private Issuer
8:04am
6-K
EX-99.1
mw6og99fc yq
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am